Bioactive LDH nanoplatforms for cancer therapy: Advances in modulating programmed cell death
- PMID: 40761508
- PMCID: PMC12320707
- DOI: 10.1016/j.mtbio.2025.102139
Bioactive LDH nanoplatforms for cancer therapy: Advances in modulating programmed cell death
Abstract
In recent years, the rapid advancement of nanotechnology and tumor biology has significantly expanded the application of nanomaterials in cancer therapy, particularly through the induction of programmed cell death (PCD) in cancer cells. Layered double hydroxides (LDH), a class of two-dimensional inorganic nanomaterials, have attracted considerable attention due to its tunable structures, excellent biocompatibility, and superior drug delivery capabilities. Emerging research has highlighted the great potential of LDH in modulating various forms of PCD. In this review, we provide a comprehensive overview of recent progress in the use of LDH to regulate different PCD pathways in cancer cells, including apoptosis, autophagy, ferroptosis, cuproptosis and pyroptosis. It emphasizes the underlying mechanisms of action, material design strategies, and the application of LDH in precise cancer therapy. Finally, this review is concluded with perspectives on the key challenges and bottlenecks of bioactive LDH in cancer therapy, providing potential solutions and outlining future perspectives.
Keywords: Cancer therapy; Layered double hydroxides; Nanomaterials; Programmed cell death.
© 2025 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures










Similar articles
-
Cuproptosis: a novel therapeutic mechanism in lung cancer.Cancer Cell Int. 2025 Jun 24;25(1):231. doi: 10.1186/s12935-025-03864-1. Cancer Cell Int. 2025. PMID: 40555995 Free PMC article. Review.
-
Potential value and cardiovascular risks of programmed cell death in cancer treatment.Front Pharmacol. 2025 Jul 3;16:1615974. doi: 10.3389/fphar.2025.1615974. eCollection 2025. Front Pharmacol. 2025. PMID: 40678726 Free PMC article. Review.
-
Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.J Cancer Res Clin Oncol. 2023 Oct;149(13):11351-11368. doi: 10.1007/s00432-023-05000-w. Epub 2023 Jun 28. J Cancer Res Clin Oncol. 2023. PMID: 37378675 Free PMC article.
-
From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies.Bioact Mater. 2025 Jul 1;52:773-809. doi: 10.1016/j.bioactmat.2025.06.052. eCollection 2025 Oct. Bioact Mater. 2025. PMID: 40677757 Free PMC article. Review.
-
Revolutionizing breast cancer treatment: Harnessing the related mechanisms and drugs for regulated cell death (Review).Int J Oncol. 2024 May;64(5):46. doi: 10.3892/ijo.2024.5634. Epub 2024 Mar 8. Int J Oncol. 2024. PMID: 38456493 Free PMC article.
References
-
- Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA: A Cancer J. Clin. 2022;72(1):7–33. - PubMed
-
- Zheng K., Song R., Li R., Liu M., Ba Y., Jiang W., Fan K. Nanomaterials for refining tumor microenvironment and enhancing therapy in head and neck squamous cell carcinoma: a review. Oncol. Translat. Med. 2024;10(4):151–161.
-
- Qin Y., Zeng W.-F., Liang W. Development of therapeutic cancer vaccines using nanomicellar preparations. Oncol. Translat. Med. 2023;9(6):265–268.
-
- Soerjomataram I., Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070. Nat. Rev. Clin. Oncol. 2021;18(10):663–672. - PubMed
-
- Bai Y., Lam H.C., Lei X. Dissecting programmed cell death with small molecules. Acc. Chem. Res. 2020;53(5):1034–1045. - PubMed
Publication types
LinkOut - more resources
Full Text Sources